Shopping Cart
- Remove All
Your shopping cart is currently empty
AMG-1694, a potent disruptor of the glucokinase–glucokinase regulatory protein (GK-GKRP) complex, operates by promoting the dissociation of this complex, thereby indirectly enhancing GK enzymatic activity with an IC50 of 7 nM. It effectively normalizes blood glucose levels in various rodent diabetes models [1] and lowers blood glucose specifically in diabetic animals without affecting normoglycemic ones. Additionally, AMG-1694 reverses the GKRP-induced inhibition of GK activity and facilitates GK translocation.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $160 | In Stock | |
| 5 mg | $370 | In Stock | |
| 10 mg | $512 | In Stock | |
| 25 mg | $735 | In Stock | |
| 50 mg | $910 | In Stock | |
| 100 mg | $1,170 | In Stock | |
| 200 mg | $1,580 | In Stock |
| Description | AMG-1694, a potent disruptor of the glucokinase–glucokinase regulatory protein (GK-GKRP) complex, operates by promoting the dissociation of this complex, thereby indirectly enhancing GK enzymatic activity with an IC50 of 7 nM. It effectively normalizes blood glucose levels in various rodent diabetes models [1] and lowers blood glucose specifically in diabetic animals without affecting normoglycemic ones. Additionally, AMG-1694 reverses the GKRP-induced inhibition of GK activity and facilitates GK translocation. |
| Targets&IC50 | GK:0.02 μM(EC50), GK-GKRP:7 nM |
| In vitro | AMG-1694 demonstrates high efficacy in reinstating the enzymatic activity of GK in the presence of GKRP with an EC50 of 0.020 μM.[1] |
| Molecular Weight | 533.63 |
| Formula | C23H30F3N3O4S2 |
| Cas No. | 1361217-07-3 |
| Smiles | C([C@@H]1N(CCN(S(=O)(=O)C2=CC=CS2)C1)C3=CC=C([C@@](C(F)(F)F)(C)O)C=C3)N4[C@@H](C)COCC4 |
| Relative Density. | 1.348 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (93.7 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.75 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.